MA71257A - Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant - Google Patents
Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenantInfo
- Publication number
- MA71257A MA71257A MA71257A MA71257A MA71257A MA 71257 A MA71257 A MA 71257A MA 71257 A MA71257 A MA 71257A MA 71257 A MA71257 A MA 71257A MA 71257 A MA71257 A MA 71257A
- Authority
- MA
- Morocco
- Prior art keywords
- itga2
- antibody
- drug conjugates
- antibodies targeting
- targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210743539 | 2022-06-27 | ||
| EP23829854.1A EP4545563A1 (fr) | 2022-06-27 | 2023-06-02 | Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant |
| PCT/CN2023/098076 WO2024001669A1 (fr) | 2022-06-27 | 2023-06-02 | Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71257A true MA71257A (fr) | 2025-04-30 |
Family
ID=89382806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71257A MA71257A (fr) | 2022-06-27 | 2023-06-02 | Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4545563A1 (fr) |
| JP (1) | JP2025524306A (fr) |
| KR (1) | KR20250042144A (fr) |
| CN (1) | CN119343378A (fr) |
| AU (1) | AU2023301621A1 (fr) |
| CA (1) | CA3259463A1 (fr) |
| CL (1) | CL2024004023A1 (fr) |
| CO (1) | CO2025000762A2 (fr) |
| IL (1) | IL317725A (fr) |
| JO (1) | JOP20240284A1 (fr) |
| MA (1) | MA71257A (fr) |
| MX (1) | MX2024016011A (fr) |
| WO (1) | WO2024001669A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2025208742A1 (en) * | 2024-01-19 | 2026-07-23 | Foreseen Technology (Beijing) Co., Ltd. | An anti_itga2 antibody drug conjugate |
| CN119241709B (zh) * | 2024-10-24 | 2025-04-01 | 兰州大学 | Itga2单克隆抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| KR101281501B1 (ko) * | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
| PL1948798T3 (pl) * | 2005-11-18 | 2015-12-31 | Glenmark Pharmaceuticals Sa | Przeciwciała przeciwko integrynie alfa2 i ich zastosowania |
| CN101294198A (zh) * | 2007-04-27 | 2008-10-29 | 上海人类基因组研究中心 | 冠心病检测方法和试剂盒 |
| WO2009100110A1 (fr) * | 2008-02-05 | 2009-08-13 | Medarex, Inc. | Anticorps alpha 5-bêta 1 et leurs utilisations |
| JP5775458B2 (ja) * | 2008-11-06 | 2015-09-09 | グレンマーク ファーマシューティカルズ, エセ.アー. | 抗α2インテグリン抗体を使用する処置 |
| RU2545401C2 (ru) * | 2010-02-23 | 2015-03-27 | Санофи | Антитела к интегрину альфа-2 и их применения |
| TWI560199B (en) * | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
-
2023
- 2023-06-02 MA MA71257A patent/MA71257A/fr unknown
- 2023-06-02 IL IL317725A patent/IL317725A/en unknown
- 2023-06-02 WO PCT/CN2023/098076 patent/WO2024001669A1/fr not_active Ceased
- 2023-06-02 AU AU2023301621A patent/AU2023301621A1/en active Pending
- 2023-06-02 EP EP23829854.1A patent/EP4545563A1/fr active Pending
- 2023-06-02 CN CN202380046400.3A patent/CN119343378A/zh active Pending
- 2023-06-02 CA CA3259463A patent/CA3259463A1/fr active Pending
- 2023-06-02 JP JP2024573733A patent/JP2025524306A/ja active Pending
- 2023-06-02 KR KR1020257002134A patent/KR20250042144A/ko active Pending
-
2024
- 2024-12-18 MX MX2024016011A patent/MX2024016011A/es unknown
- 2024-12-22 JO JOJO/P/2024/0284A patent/JOP20240284A1/ar unknown
- 2024-12-24 CL CL2024004023A patent/CL2024004023A1/es unknown
-
2025
- 2025-01-24 CO CONC2025/0000762A patent/CO2025000762A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20240284A1 (ar) | 2024-12-22 |
| JP2025524306A (ja) | 2025-07-29 |
| EP4545563A1 (fr) | 2025-04-30 |
| CL2024004023A1 (es) | 2025-07-25 |
| KR20250042144A (ko) | 2025-03-26 |
| WO2024001669A1 (fr) | 2024-01-04 |
| CA3259463A1 (fr) | 2025-04-18 |
| IL317725A (en) | 2025-02-01 |
| CN119343378A (zh) | 2025-01-21 |
| MX2024016011A (es) | 2025-04-02 |
| WO2024001669A9 (fr) | 2024-11-14 |
| CO2025000762A2 (es) | 2025-04-16 |
| AU2023301621A1 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3941945A4 (fr) | Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant | |
| EP3877416A4 (fr) | Anticorps anti-cd45 et leurs conjugués | |
| EP3941946A4 (fr) | Anticorps anti-claudine-6 et conjugués de médicaments | |
| IL290979A (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
| EP3936501C0 (fr) | Conjugaison d'anticorps spécifique à un site et conjugué anticorps-médicament servant d'exemple spécifique de celui-ci | |
| EP4161582A4 (fr) | Conjugués anticorps-médicament contenant un anticorps anti-mésothéline et leurs utilisations | |
| IL299362A (en) | Antibody-drug conjugates that include anti-H3-B7 antibodies | |
| EP3638697A4 (fr) | Anticorps anti-il1rap et conjugués anticorps-médicament | |
| IL300176A (en) | Anti-cd228 antibodies and antibody-drug conjugates | |
| KR20240001074A9 (ko) | 하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체 | |
| EP4043034A4 (fr) | Conjugué anticorps-médicament de ciblage de lysosome et utilisation correspondante | |
| PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
| EP4247425A4 (fr) | Anticorps modifié, conjugué anticorps-médicament et son utilisation | |
| IL284673A (en) | Traceless linkers and protein-conjugates thereof | |
| EP4279505A4 (fr) | Anticorps monoclonal ciblant le cd276 humain et son application | |
| EP4323009A4 (fr) | Lieurs, conjugués et leurs applications | |
| MA49987A (fr) | Préparation de conjugué anticorps-médicament et lyophilisation associée | |
| EP3735271A4 (fr) | Anticorps anti-facteur tissulaire, conjugués anticorps-médicament et procédés associés | |
| IL284974A (en) | Anti-cd228 antibodies and antibody-drug conjugates | |
| MA49273A (fr) | Anticorps anti-tmeff1 et conjugués anticorps-médicament | |
| EP4188449A4 (fr) | Conjugués anticorps-médicament anti-tm4sf1 comprenant des lieurs clivables et leurs méthodes d'utilisation | |
| EP3995496A4 (fr) | Médicament de camptothécine et un conjugué d'anticorps de celui-ci | |
| EP4458850A4 (fr) | Anticorps anti-ror1, conjugué anticorps anti-ror1-médicament et leurs utilisations médicales | |
| EP4335873A4 (fr) | Anticorps anti-claudine 18.2 et conjugué anticorps-médicament de celui-ci | |
| EP4188544A4 (fr) | Formulations d'anticorps anti-connexine |